A Phase I, Open-label, Multicenter, First in Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients with Advanced Malignancies
ACTRN 12622001339741 Brief Summary This is a first in human study of…
Read more arrow_forwardACTRN 12622001339741 Brief Summary This is a first in human study of…
Read more arrow_forwardNCT 06815575 Brief Summary This is a multi-centre, two-part, open-label, phase 1,…
Read more arrow_forwardACTRN 12618001074280 Brief Summary This study’s purpose is to facilitate and expedite…
Read more arrow_forwardNCT 05981703 Brief Summary This is an open-label, multicenter, and nonrandomized dose…
Read more arrow_forwardNCT 06929663 Brief Summary This is an first-in-human, Phase I clinical study…
Read more arrow_forwardNCT 05094336 Brief Summary The primary objective of Parts 1 and 2…
Read more arrow_forwardNCT 06669975 Brief Summary This is a Phase 1/2, multi-regional, multi-center, open-label,…
Read more arrow_forwardNCT 06130553 Brief Summary This is a first time in human (FTiH)…
Read more arrow_forwardNCT 06803680 Brief Summary The goal of this clinical trial is to…
Read more arrow_forwardNCT 05346484 Brief Summary This is an open-label, dose-escalation, multi-center phase I…
Read more arrow_forward